Subscribe to RSS
DOI: 10.1055/s-2006-926233
A Versatile Synthesis of (±)-Deoxyfebrifugine, an Antimalarial Alkaloid Analogue, and Related Compounds
Publication History
Publication Date:
06 February 2006 (online)
![](https://www.thieme-connect.de/media/synlett/200603/lookinside/thumbnails/10.1055-s-2006-926233-1.jpg)
Abstract
The title compound was prepared by a simple route involving Eschenmoser sulfide contraction between 3-(3-bromo-2-oxopropyl)quinazolin-4(3H)-one (11) and piperidine-2-thione (13) followed by chemoselective catalytic hydrogenation. This short but flexible procedure also permitted access to N-alkyl analogues, and to analogues in which the piperidine ring was replaced by other saturated nitrogen-containing heterocycles.
Key words
alkaloids - enaminones - heterocycles - piperidines - quinazolines
-
1a
Jang CS.Fu FY.Wang CY.Huang KC.Lu G.Chou TC. Science 1946, 103: 59 -
1b
Koepfli JB.Mead JF.Brockman JA. J. Am. Chem. Soc. 1947, 69: 1837 -
1c
Kuehl FA.Spencer CF.Folkers K. J. Am. Chem. Soc. 1948, 70: 2091 -
1d
Koepfli JB.Mead JF.Brockman JA. J. Am. Chem. Soc. 1949, 71: 1048 -
1e
Koepfli JB.Brockman JA.Moffat J. J. Am. Chem. Soc. 1950, 72: 3323 -
2a
Ablondi F.Gordon S.Morton J.Williams JH. J. Org. Chem. 1952, 17: 14 -
2b
Hutchings EL.Gordon S.Ablondi F.Wolf CF.Williams JH. J. Org. Chem. 1952, 17: 19 -
2c
Kato M.Inaba M.Itahana H.Ohara E.Nakamura K.Uesato S.Inouye H.Fujita T. Shoyakugaku Zasshi 1990, 44: 288 ; Chem. Abstr. 1991, 115, 64012f -
2d
Khalil AT.Chang F.-R.Lee Y.-H.Chen C.-Y.Liaw C.-C.Ramesh P.Yuan S.-SF.Wu Y.-C. Arch. Pharm. Res. 2003, 26: 15 - 3
Takeuchi Y.Harayama T. Trends Heterocycl. Chem. 2001, 7: 65 -
4a
Kobayashi S.Ueno M.Suzuki R.Ishitani H. Tetrahedron Lett. 1999, 40: 2175 -
4b
Kobayashi S.Ueno M.Suzuki R.Ishitani H.Kim H.-S.Wataya Y. J. Org. Chem. 1999, 64: 6833 -
5a
Murata K.Takano F.Fushiya S.Oshima Y. J. Nat. Prod. 1998, 61: 729 -
5b
Murata K.Takano F.Fushiya S.Oshima Y. Biochem. Pharm. 1999, 58: 1593 -
6a
Hirai S.Kikuchi H.Kim H.-S.Begum K.Wataya Y.Tasaka H.Miyazawa Y.Yamamoto K.Oshima Y. J. Med. Chem. 2003, 46: 4351 -
6b
Kikuchi H.Tasaka H.Hirai S.Takaya Y.Iwabuchi Y.Ooi H.Hatakeyama S.Kim H.-S.Wataya Y.Oshima Y. J. Med. Chem. 2002, 45: 2563 -
6c
Takeuchi Y.Koike M.Azuma K.Nishioka H.Abe H.Kim H.-S.Wataya Y.Harayama T. Chem. Pharm. Bull. 2001, 49: 721 -
6d
Takaya Y.Tasaka H.Chiba T.Uwai K.Tanitsu M.Kim H.-S.Wataya Y.Miura M.Takeshita M.Oshima Y. J. Med. Chem. 1999, 42: 3163 ; and references cited therein - 7
Edeson JFB.Wilson T. Trans. R. Soc. Trop. Med. Hyg. 1955, 49: 543 - For recent syntheses of optically active or racemic febrifugine, see the following:
-
8a
Takeuchi Y.Oshige M.Azuma K.Abe H.Harayama T. Chem. Pharm. Bull. 2005, 53: 868 -
8b
Ashoorzadeh A.Caprio V. Synlett 2005, 346 -
8c
Katoh M.Matsune R.Nagase H.Honda T. Tetrahedron Lett. 2004, 45: 6221 -
8d
Huang P.-Q.Wei B.-G.Ruan Y.-P. Synlett 2003, 1663 -
8e
Sugiura M.Hagio H.Hirabayashi R.Kobayashi S. Synlett 2001, 1225 -
8f
Ooi H.Urushibara A.Esumi T.Ibabuchi Y.Hatakeyama S. Org. Lett. 2001, 3: 953 -
8g
Sugiura M.Kobayashi S. Org. Lett. 2001, 3: 477 -
8h
Okitsu O.Suzuki R.Kobayashi S. J. Org. Chem. 2001, 66: 809 -
8i
Takeuchi Y.Azuma K.Takakura K.Abe H.Kim H.-S.Wataya Y.Harayama T. Tetrahedron 2001, 57: 1213 -
8j
For syntheses published prior to 2001, see the references cited in the preceding.
-
9a
Jiang S.Zeng Q.Gettayacamin M.Tungtaeng A.Wannaying S.Lim A.Hansukjariya P.Okunji CO.Zhu S.Fang D. Antimicrob. Agents Chemother. 2005, 49: 1169 -
9b
Chien P.-L.Cheng CC. J. Med. Chem. 1970, 13: 867 -
9c
Fishman M.Cruickshank PA. J. Med. Chem. 1970, 13: 155 -
9d
Baker BR.Schaub RE.Joseph JP.McEvoy FJ.Williams JH. J. Org. Chem. 1953, 18: 133 ; and references cited therein - 10
Takeuchi Y.Tokuda S.Takagi T.Koike M.Abe H.Harayama T.Shibata Y.Kim H.-S.Wataya Y. Heterocycles 1999, 51: 1869 - 11 Review:
Michael JP.de Koning CB.Gravestock D.Hosken GD.Howard AS.Jungmann CM.Krause RWM.Parsons AS.Pelly SC.Stanbury TV. Pure Appl. Chem. 1999, 71: 979 - 12
Michael JP.de Koning CB.van der Westhuyzen CW. Org. Biomol. Chem. 2005, 3: 836 ; and references cited therein -
13a
Roth M.Dubs P.Götschi E.Eschenmoser A. Helv. Chim. Acta 1971, 54: 710 -
13b
Shiosaki K. In Comprehensive Organic Synthesis Vol. 2:Trost BM. Pergamon Press; Oxford: 1991. p.865-892 - 14
von Niementowski S. J. Prakt. Chem. 1895, 51: 564 - 15
Weygand F.Schmied-Kowarzik V. Chem. Ber. 1949, 82: 333 - 16
Brillon D. Synth. Commun. 1990, 20: 3085 - 17
Honda T.Kimura M. Org. Lett. 2000, 2: 3925 -
20a
Baker BR.Querry MV.Schaub RE.Williams JH. J. Org. Chem. 1952, 17: 58 -
20b For an alternative synthesis of (±)-deoxyfebrifugine from the same group, see:
Baker BR.Querry MV.Kadish AF.Williams JH. J. Org. Chem. 1952, 17: 52 - 21
Baker BR.Schaub RE.Querry MV.Williams JH. J. Org. Chem. 1952, 17: 97 - 22
Ghirlando R.Howard AS.Katz RB.Michael JP. Tetrahedron 1984, 40: 2879 -
24a
Baker BR.Schaub RE.Williams JH. J. Org. Chem. 1952, 17: 109 -
24b
Baker BR.Schaub RE.Williams JH. J. Org. Chem. 1952, 17: 116
References and Notes
Synthesis of 3-[(3
Z
)-2-Oxo-3-(piperidin-2-ylidene)propyl]quinazolin-4 (3
H
)-one (
15).
A mixture of 3-(3-bromo-2-oxopropyl)quinazolin-4 (3H)-one (11, 395 mg, 1.41 mmol) and piperidine-2-thione (13, 163 mg, 1.41 mmol) in dry THF (30 mL) was stirred at r.t. for 48 h until salt precipitation was complete. After evaporation of the solvent in vacuo, dry MeCN (25 mL), triphenylphosphine (PPh3, 0.92 g, 3.5 mmol) and 1-methylpiperidine (0.44 mL, 3.5 mmol) were sequentially added to the residue. Stirring was continued at r.t. for another 18 h. After evaporation of the solvent in vacuo, the residue was dissolved in CH2Cl2 (50 mL) and extracted with aq HCl (2 M, 3 × 20 mL). The combined aqueous extracts were washed with CH2Cl2 (10 mL), then made basic with concd aq NH3 solution. Extraction with CH2Cl2 (3 × 15 mL) was followed by washing of the combined organic extracts with brine (10 mL). Drying (Na2SO4), filtering and evaporation to dryness yielded crude product as a light brown solid, which was purified by column chromatography (EtOAc-hexane, 4:1) to afford 15 as a colourless solid (254 mg, 64%), mp 167.5-170 °C (from EtOAc-hexane) (lit. mp of the putative tautomer 16,
[20]
167-170 °C; 176-178 °C after recrystallisation). MS: m/z calcd for C16H17N3O2: 283.1321; found: 283.1326 [M+]. IR (CHCl3): νmax = 2948, 2869, 1673 (s, quinazolinone C=O), 1607 (s, enaminone C=O), 1578, 1526, 1474 cm-1. 1H NMR (300 MHz, CDCl3): δ = 11.11 (1 H, br s, NH), 8.31 (1 H, d, J = 8.3 Hz, H-5), 8.04 (1 H, s, H-2), 7.71-7.78 (2 H, m, H-7 and H-8), 7.45-7.51 (1 H, m, H-6), 4.93 (1 H, s, NC=CH), 4.64 (2 H, s, O=CCH
2), 3.32 (2 H, dt, J = 5.7, 2.3 Hz, ring NCH
2), 2.39 (2 H, t, J = 6.2 Hz, NCCH
2), 1.67-1.81 (4 H, m, 2 × ring CH
2). 13C NMR: δ = 186.0 (enaminone C=O), 166.5 (NC=CH), 161.1 (quinazolinone C=O), 148.3, 147.2, 134.1, 127.4, 127.0, 126.8, 122.1, 90.2 (NC=CH), 52.4 (O=CCH2), 41.1 (ring NCH2), 28.5, 21.9, 18.9. MS (EI): m/z (%) = 283 (9) [M+], 255 (2), 220 (3), 124 (100), 82 (4), 55 (3).
Results of a more extensive crystallographic survey that includes 15 and representative examples of compounds 19 and 21 will be published elsewhere.
23
Synthesis of (±)-Deoxyfebrifugine (
5).
Enaminone 15 (190 mg, 0.671 mmol) was dissolved in a mixture of MeOH (15 mL) and aq HCl (8.5 N, 0.20 mL). The solution was stirred over pre-hydrogenated PtO2·xH2O (Adams catalyst, 26 mg) under H2 gas (3 atm) for 6 h. After filtering through Celite®, the solvent was removed under reduced pressure and the residue was triturated with EtOH-MeOH (5:1), cooled down and left to precipitate overnight in the freezer. After filtering, the precipitate was identified as the dihydrochloride salt of (±)-deoxyfebrifugine, 5·2HCl (138 mg, 58%), mp 218-221 °C (decomp.) [lit. mp 228-230 °C (decomp.)
[20]
]. 1H NMR (300 MHz, D2O): δ = 8.65 (1 H, s, H-2), 8.28 (1 H, d, J = 8.1 Hz, H-5), 8.04 (1 H, m, H-6), 7.74-7.83 (2 H, m, H-7 and H-8), 5.20 (2 H, s, O=CCH
2N), 3.70 (1 H, m, J = 7.1 Hz, NCH), 3.05-3.49 (4 H, m, ring NCH
2 and O=CCH
2CH), 1.92-2.11 (3 H, m, 1.5 × ring CH
2), 1.59-1.75 (3 H, m, 1.5 × ring CH
2). 13C NMR (50 MHz, D2O): δ = 204.4, 163.5, 151.7, 144.6, 139.2, 132.0, 129.4, 125.9, 122.5, 58.2, 54.7, 47.6, 45.1, 30.7, 24.3, 24.0. The salt was dissolved in sat. K2CO3 solution (5 mL), and the resulting solution was extracted with EtOAc (3 × 10 mL). The combined extracts were dried (MgSO4), filtered and evaporated in vacuo to give the free base as a cream-coloured solid which could be repeatedly recrystallised from EtOAc-hexane to afford (±)-deoxyfebrifugine (5) in quantitative yield from the hydrochloride salt; colourless needles, mp 127.5-129 °C (lit.
[10]
mp 139-141 °C; lit.
[20]
138-140 °C). MS: m/z calcd for C16H20N3O2: 286.1556; found: 286.1559 [MH+]. IR (film) νmax = 3063 (w), 2930 (m), 2854 (w), 1729 (m), 1677 (s), 1613 (s), 1563 (w), 1474 (m) cm-1. 1H NMR (300 MHz, CDCl3): δ = 8.28 (1 H, d, J = 8.1 Hz, H-5), 7.89 (1 H, s, H-2), 7.72-7.80 (2 H, m, H-7 and H-8), 7.51 (1 H, dt, J = 7.3, 1.4 Hz, H-6), 4.84 (1 H, d, J = 17.4 Hz, O=CCH
a
HbN), 4.73 (1 H, d, J = 17.4 Hz, O=CCHa
H
b
N), 3.04 (2 H, 2 × m, NCH and O=CCH
a
HbCH), 2.64-2.67 (3 H, m, ring NCH
2 and O=CCHa
H
b
CH), 2.11 (1 H, br s, NH), 1.80 (1 H, br d, ring CH
a
Hb), ca. 1.64, 1.40, 1.23 (2 H, 2 H, 1 H, 3 × m, remaining ring CH
2). 13C NMR: δ = 202.1, 160.9, 148.2, 146.2, 134.5, 127.6, 127.4, 126.7, 121.8, 54.8, 52.7, 47.7, 46.7, 32.7, 26.0, 24.5. FAB-MS: m/z (%) = 286 (25) [MH+], 180 (5), 154 (100), 136 (74), 124 (9), 120 (13), 115 (5), 107 (26). The 1H NMR spectroscopic data agree with those reported in the literature.
[10]